Glaxo to reduce U.S. sales force
British drug maker GlaxoSmithKline is restructuring its U.S. operations, starting with reducing its U.S. sales force by 1,000, following many of its top competitors in eliminating sales jobs.
The world’s No. 2 drug maker by revenue also will switch from having dual U.S. headquarters, in Philadelphia and in Research Triangle Park, N.C., to operating just the North Carolina headquarters.
Spokeswoman Mary Anne Rhyne said the headquarters change was meant to eliminate confusion and was largely symbolic. There are currently no plans to cut jobs in Philadelphia related to the headquarters move, she said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
